Pfizer China to sell biologics DS, DP manufacturing facilities to WuXi Biologics
Hangzhou: WuXi Biologics has recently announced that the company has entered into an equity agreement with Pfizer China ("Pfizer") to acquire its state-of-the-art biologics manufacturing facilities as well as its labor force in Hangzhou, China.
The transaction is expected to close in the first half of 2021, which will immediately boost the commercial Drug Substance (DS) and Drug Product (DP) capacities for WuXi Biologics to address surging manufacturing demands.
The state-of-the-art 50,000 m2 facilities, GMP operational since 2018, includes DS capacities equipped with 2x2000L single-use bioreactors expandable to 4x2000L (MFG20) and DP capacities of vial filling (DP9) and pre-filled syringe (DP10). Leveraging the facilities' experienced workforce and WuXi Biologics' extensive expertise in manufacturing and regulation, the production is expected to commence shortly after the deal closure.
Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are pleased to work with Pfizer and add the new Hangzhou biologics manufacturing facilities to our global network to address the surging manufacturing demands for late-stage and commercial projects due to the success of our Win-the-Molecule strategy. Globally DS and especially DP capacities are in urgent need now. The acquisition will allow us to better enable our global partners to develop and manufacture premier-quality biologics to benefit patients around the world."
Read also: Pfizer can help offset AstraZeneca vaccine delays: EU industry commissioner Thierry Breton
WuXi Biologics, a Hong Kong-listed company, is a global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing.
Next Story
